How Durable Are CAR T-Cell Therapies? – OncLive
OncLive |
How Durable Are CAR T-Cell Therapies?
OncLive The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta) in 2017, this … |
